Odimma

What Odimma does

Odimma Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Strasbourg, France, developing personalized cancer immunotherapies with lead candidate ODI-2001. The company's platform combines AI-driven neoantigen selection (via partner myNEO), synthetic DNA manufacturing using Touchlight's dbDNA technology, a Modified Vaccinia Ankara (MVA) viral vector component supplied by ABL Europe and Oxford Biomedica, and an anti-CTLA4 immune checkpoint inhibitor antibody, designed to deliver a three-in-one synergistic formulation with an 8-week biopsy-to-treatment timeline and 5-day DNA production turnaround. Odimma targets treatment-resistant solid tumors including melanoma, colorectal cancer, and breast cancer, addressing the approximately 80% of cancer patients who do not respond to current immunotherapy approaches, with the platform described as modular and expandable to additional oncology indications and infectious diseases.

Odimma operates a clinical-stage, partnership-driven business model with no disclosed commercial revenue. The company runs investigator-initiated clinical trials sponsored by French cancer centers, with ANSM authorizing the Phase I trial of ODI-2001 at Centre Georges François Leclerc (CGFL) in February 2026. Go-to-market is built around strategic alliances with technology and manufacturing partners (Touchlight, myNEO, ABL Europe, Oxford Biomedica, Genomescan), ecosystem organizations (Paris Saclay Cancer Cluster, France 2030, Canceropole-Est), and a mix of institutional and angel investors (Cap Innov'Est, Bpifrance, Capital Grand Est, Alsace Business Angels, Angels Santé). Future revenue is expected to flow through pharmaceutical licensing, co-development partnerships, and potential commercialization of personalized cancer treatments, though pricing remains undisclosed pending regulatory approval.

As of the available data, Odimma has secured €4 million across two seed financing rounds (December 2019 and May 2023) and operates with a team of 1-10 employees drawing on senior immuno-oncology expertise from Transgene alumni and regulatory expertise from a former ANSM Biologics Director and EMA Committee for Advanced Therapies member. The company has earned the European Commission Seal of Excellence (2024), a Merck Group Special Prize at BioFIT 2022, and recognition in Challenges magazine's '100 Start-ups to Invest in 2021,' positioning it within the French precision oncology ecosystem with explicit international expansion signals via the France 2030 Export Program.

Name

Odimma

Legal name

ODIMMA THERAPEUTICS

Website

https://odimma-therapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Odimma Therapeutics is a clinical-stage French biotech developing ODI-2001, a personalized cancer immunotherapy combining AI-driven neoantigen selection, synthetic DNA, MVA viral vector, and anti-CTLA4 antibody for treatment-resistant solid tumors.

Ownership category

akta.pro rank

Product category

Personalized Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Personalized cancer immunotherapy
• Neoantigen-based therapy
• Synthetic DNA manufacturing
• Precision oncology platform
• Clinical-stage biotechnology

Headquarters

HQ city

Illkirch-graffenstaden

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Personalized Cancer Immunotherapy Development: As a clinical-stage biotechnology company, Odimma is developing ODI-2001 personalized immunotherapy for cancer treatment. Revenue will be generated through future pharmaceutical licensing, co-development partnerships, and potential commercialization of personalized cancer treatments. Currently pre-revenue, focused on advancing through Phase I clinical trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Odimma Therapeutics is developing personalized cancer immunotherapies through its lead clinical candidate ODI-2001, which combines AI-driven neoantigen selection, synthetic DNA vectors encoding patient-specific neoantigens, an MVA viral component for immune stimulation, and an anti-CTLA4 antibody checkpoint inhibitor. The product is delivered as a personalized treatment manufactured for each individual patient from tumor biopsy within an 8-week timeline, targeting treatment-resistant solid tumors including melanoma, colorectal, and breast cancers. The company is currently advancing ODI-2001 through an ANSM-authorized Phase I clinical trial sponsored by the Centre Georges François Leclerc (CGFL) in Dijon, France.

Product overview

Odimma Therapeutics is developing a precision immunotherapy platform centered on ODI-2001, its lead clinical program. ODI-2001 is a personalized cancer immunotherapy combining three immune components: synthetic DNA vectors encoding patient-specific neoantigens identified through AI-assisted selection, an MVA viral component for immune stimulation, and an anti-CTLA4 antibody for sustained immune activation. The platform is designed to transform tumor genomic data into individualized therapeutic strategies for treatment-resistant cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• ODI-2001 Lead clinical-stage personalized cancer immunotherapy candidate that combines three synergistic components for each patient: (1) synthetic DNA vectors encoding AI-selected patient-specific neoantigens, (2) a Modified Vaccinia Ankara (MVA) viral vector for immune stimulation, and (3) an anti-CTLA4 antibody for sustained immune checkpoint blockade. Designed for patients with treatment-resistant solid tumors including melanoma, colorectal and breast cancers, delivered within an 8-week biopsy-to-treatment timeline through GMP manufacturing partners (Touchlight for dbDNA, ABL Europe for MVA). Currently in ANSM-authorized Phase I clinical trial at Centre Georges François Leclerc (CGFL).

Quantifiable outcome

• 80% of cancer patients do not respond to current immunotherapy approaches - ODI-2001 targets this unmet need
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered strategic, core and supporting.

• France 2030 Export ProgramstrategicStrategic or Co-development Partner · 27 November 2025National initiative supporting high-potential French innovators in accelerating international development, strategic partnerships, and future clinical expansion. Supports Odimma's efforts to strengthen international visibility and expand strategic collaborations globally.
• Paris Saclay Cancer Cluster (PSCC)strategicStrategic or Co-development Partner · 12 December 2024Selected among 10 new oncology-focused projects supported by the first European biocluster dedicated exclusively to oncology innovation. Provides access to expertise, infrastructure, scientific resources and strategic support within France's leading oncology innovation ecosystem.
• myNEOcoreTechnology or Integration · 13 February 2023Strategic clinical collaboration combining Odimma's synthetic DNA immunotherapy technology with myNEO's AI-driven neoantigen discovery platform. Supports identification and selection of patient-specific neoantigen targets for ODI-2001 development in solid tumors through planned Phase I and Phase II clinical studies.
• TouchlightcoreTechnology or Integration · 7 December 2022Strategic partnership providing access to Touchlight's proprietary doggybone DNA (dbDNA™) technology for synthetic DNA manufacturing. Enables DNA production in as little as five days, providing speed and scalability required for personalized immunotherapy approaches. Supports clinical-grade DNA production for ODI-2001 neoantigen-based immunotherapy.
• ABL EuropecoreTechnology or Integration · 17 April 2022Strategic development agreement for viral vector manufacturing. ABL manufactures the MVA viral component of ODI-2001, a key element designed to stimulate the immune system and deliver patient-specific neoantigen DNA. Production of GMP-grade material supports clinical development.
• GenomescansupportingTechnology or IntegrationTechnology and manufacturing partner for tumor sequencing services supporting neoantigen identification workflow.
• Oxford Biomedica (OXB)supportingTechnology or IntegrationProvider of MVA viral component technology for immunotherapy formulation.
• Canceropole-EstsupportingStrategic or Co-development PartnerEcosystem and innovation support partner within the regional cancer research cluster.
• Quest for HealthsupportingStrategic or Co-development PartnerEcosystem and innovation support partner associated with WiClub Health funding initiative.

Scale indicators4 records

Recent moves7 records

Expansion highlights1 record

Emerging players

• EpiVax: EpiVax provides AI-driven neoantigen prediction and immunogenicity tools (similar to Odimma's myNEO partnership), positioning it as an enabling/competing neoantigen-selection technology provider in the same therapeutic category.

Direct peers

• Nouscom: European clinical-stage biotech developing personalized neoantigen cancer vaccines using viral vector platforms, directly comparable in modality, indication focus, and company stage to Odimma.
• Gritstone bio: Gritstone's SLATE and GRANITE programs are personalized neoantigen immunotherapies using viral vectors (including chimpanzee adenovirus prime / MVA boost) plus checkpoint inhibition — closely analogous to Odimma's prime-boost + anti-CTLA4 architecture.
• BioNTech: BioNTech's BNT122 (Autogene cevumeran) is the leading personalized neoantigen mRNA cancer vaccine, sharing Odimma's core mechanism of patient-specific neoantigen delivery and is the benchmark competitor in this category.
• Transgene: French clinical-stage biotech developing MVA-based therapeutic cancer vaccines (e.g., TG4050, a personalized neoantigen MVA vaccine). Shares Odimma's MVA vector foundation, French base, and several former senior team members.
• CureVac: German mRNA technology company developing personalized cancer vaccines (CVGBM, CVneo) — competes with Odimma in the personalized neoantigen space from a much larger capitalization base.
• Moderna: Moderna's mRNA-4157 (V940), partnered with Merck, is a personalized neoantigen mRNA vaccine in late-stage oncology trials — directly comparable to Odimma's personalized neoantigen immunotherapy approach.
• Nykode Therapeutics (formerly Vaccibody): Nykode develops DNA-based personalized neoantigen cancer vaccines using a modular vaccine platform, comparable to Odimma's DNA-based personalized immunotherapy approach and indication focus.

Broad incumbents

• Roche: Roche commercializes ipilimumab (Yervoy), the anti-CTLA4 antibody Odimma's platform is built around, and is broadly active in personalized cancer immunotherapy partnerships — relevant as a benchmark incumbent and potential partner.
• Merck KGaA: Large oncology and immunology incumbent that awarded Odimma the BioFIT 2022 Merck Special Prize and operates across immuno-oncology with broad checkpoint inhibitor and cancer vaccine programs — a potential future commercial partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/odimma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Odimma